Table 2.
Baseline clinical characteristics and parameters of insulin sensitivity under hyperinsulinemic euglycemic clamp at 80 mU/m2·min
| Parameters | Young group (n=10)a | Elderly group (n=13)a | P-valueb |
|---|---|---|---|
| Baseline insulin (mU/L) | 10.8±6.0 (55.8) | 8.3±3.2 (39.0) | 0.250 |
| Baseline C-peptide (ng/mL) | 1.2±0.5 (38.6) | 1.2±0.2 (20.5) | 0.721 |
| Fasting glucose (mg/dL) | 93.0±6.6 (7.1) | 95.4±6.1 (6.4) | 0.380 |
| Glucose (mg/dL) at 2 hours during OGTT | 104.4±15.2 (14.6) | 106.2±29.7 (28.0) | 0.867 |
| AST (U/L) | 22.6±9.2 (40.7) | 26.8±11.2 (41.8) | 0.351 |
| ALT (U/L) | 21.0±16.4 (78.1) | 22.2±9.5 (42.6) | 0.823 |
| ALP (U/L) | 68.1±33.7 (49.5) | 62.7±12.9 (20.6) | 0.640 |
| GGT (U/L) | 17.0±4.8 (28.1) | 31.8±13.6 (42.7) | 0.002 |
| Total cholesterol (mg/dL) | 165.0±28.6 (17.3) | 198.4±29.5 (14.9) | 0.013 |
| TG (mg/dL) | 96.7±49.6 (51.3) | 115.5±51.9 (44.9) | 0.391 |
| HDL (mg/dL) | 64.6±10.8 (16.7) | 51.3±10.1 (19.7) | 0.006 |
| LDL (mg/dL) | 89.9±24.1 (26.8) | 123.2±13.6 (42.7) | 0.005 |
| HbA1c (%) | 5.2±0.2 (3.6) | 5.4±0.3 (5.2) | 0.029 |
| M-value (mg/kg body weight·min) |
10.8±3.6 (32.8) | 9.9±2.7 (27.5) | 0.458 |
| M-value (mg/kg FFM· min) |
13.1±4.1 (31.3) | 12.9±3.5 (27.3) | 0.900 |
| Matsuda index | 6.4±2.7 (43.0) | 5.2±1.6 (29.8) | 0.248 |
| HOMA-IR | 1.6±0.6 (39.7) | 1.3±0.3 (23.7) | 0.185 |
Notes: aValues are presented as mean ± SD (CV, %). bP<0.05 was considered significantly different between two age groups.
Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; CV, coefficient of variation; GGT, gamma-glutayltransferase; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance; LDL, low-density lipoprotein; FFM, fat-free mass; OGTT, oral glucose tolerance test; TG, triglyceride.